Korean J Urol.  2012 May;53(5):310-316.

Surgical Experience with Retroperitoneal Liposarcoma in a Single Korean Tertiary Medical Center

• Na JC
• Choi KH
• Yang SC
• Han WK

Abstract

PURPOSE
This is a report of the surgical treatment and prognosis of retroperitoneal liposarcoma (RPLS) in Koreans.
MATERIALS AND METHODS
Nineteen patients treated for RPLS between July 1, 1984, and March 31, 2009, were included. Patient demographics, histopathologic subtypes, survival rate, disease recurrence rate and interval, and adjuvant therapy were reviewed and analyzed.
RESULTS
Of the 19 patients diagnosed with RPLS, 26.3% presented with well-differentiated RPLS, 10.5% with dedifferentiated RPLS, 15.8% with myxoid/round cell type, and 47.4% with mixed-type liposarcoma. The mean follow-up period was 66.8 months (range, 6 to 165 months). Primary RPLS was treated in 17 patients. Nine patients (52.9%) had recurrent disease, and recurrence developed at a mean of 47.7 months after primary or repeated surgical treatment. The overall survival rate was 84.2% during a mean follow-up of 66.8 months. The 3- and 5-year survival rates were 86.9%, and the 10-year survival rate was 69.5%. The recurrence interval was significantly shorter in recurrent RPLS cases (p=0.023). The mean growth rate of locally recurrent tumors was 0.34 cm per month.
CONCLUSIONS
The survival rates reported here were higher than in previous studies. Locally recurrent tumors presented with a low growth rate, which may have contributed to the relatively high survival rate. A high prevalence of mixed-type RPLS was also noted, and its cause and prognosis require further research.

Keyword

Follow-up studies; Liposarcoma; Retroperitoneal liposarcoma; Retroperitoneal neoplasms; Sarcoma

MeSH Terms

Demography
Follow-Up Studies
Humans
Liposarcoma
Prevalence
Prognosis
Recurrence
Retroperitoneal Neoplasms
Sarcoma
Survival Rate
Liposarcoma
Retroperitoneal Neoplasms

Figure

• 

  FIG. 1 Survival rate; The average survival was 223.8 months and the overall survival survival rate was 84.2%. The 5-year survival rate was 86.9%, and the 10-year survival rate was 69.5%.

• 

  FIG. 2 The interval of disease recurrence. RPLS, retroperitoneal liposarcoma.

Reference

1. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998. 228:355–365.

2. Porter GA, Baxter NN, Pisters PW. Retroperitoneal sarcoma: a population-based analysis of epidemiology, surgery, and radiotherapy. Cancer. 2006. 106:1610–1616.

3. Nathan H, Raut CP, Thornton K, Herman JM, Ahuja N, Schulick RD, et al. Predictors of survival after resection of retroperitoneal sarcoma: a population-based analysis and critical appraisal of the AJCC staging system. Ann Surg. 2009. 250:970–976.

4. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003. 238:358–370.

5. Neuhaus SJ, Barry P, Clark MA, Hayes AJ, Fisher C, Thomas JM. Surgical management of primary and recurrent retroperitoneal liposarcoma. Br J Surg. 2005. 92:246–252.

6. Lee SY, Goh BK, Teo MC, Chew MH, Chow PK, Wong WK, et al. Retroperitoneal liposarcomas: the experience of a tertiary Asian center. World J Surg Oncol. 2011. 9:12.

7. Milone M, Pezzullo LS, Salvatore G, Pezzullo MG, Leongito M, Esposito I, et al. Management of high-grade retroperitoneal liposarcomas: personal experience. Updates Surg. 2011. 63:119–124.

8. Han HH, Choi KH, Kim DS, Jeong WJ, Yang SC, Jang SJ, et al. Retroperitoneal giant liposarcoma. Korean J Urol. 2010. 51:579–582.

9. Goss G, Demetri G. Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care. Surg Oncol. 2000. 9:53–59.

10. Zlotecki RA, Katz TS, Morris CG, Lind DS, Hochwald SN. Adjuvant radiation therapy for resectable retroperitoneal soft tissue sarcoma: the University of Florida experience. Am J Clin Oncol. 2005. 28:310–316.

11. Paryani NN, Zlotecki RA, Swanson EL, Morris CG, Grobmyer SR, Hochwald SN, et al. Multimodality local therapy for retroperitoneal sarcoma. Int J Radiat Oncol Biol Phys. 2012. 82:1128–1134.

12. Eilber FC, Eilber FR, Eckardt J, Rosen G, Riedel E, Maki RG, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg. 2004. 240:686–695.

13. Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005. 41:2853–2860.

14. Fletcher CD, Unni KK, Mertens F. Pathology and genetics of tumours of soft tissue and bone. 2002. Lyon: IARCPress.

15. Cho SY, Moon KC, Cheong MS, Kwak C, Kim HH, Ku JH. Significance of microscopic margin status in completely resected retroperitoneal sarcoma. J Urol. 2011. 186:59–65.

16. Avances C, Mottet N, Mahatmat A, Chapuis E, Serre I, Culine S. Prognostic factors for first recurrence in patients with retroperitoneal sarcoma. Urol Oncol. 2006. 24:94–96.

17. Pirayesh A, Chee Y, Helliwell TR, Hershman MJ, Leinster SJ, Fordham MV, et al. The management of retroperitoneal soft tissue sarcoma: a single institution experience with a review of the literature. Eur J Surg Oncol. 2001. 27:491–497.

18. van Dalen T, Plooij JM, van Coevorden F, van Geel AN, Hoekstra HJ, Albus-Lutter Ch, et al. Long-term prognosis of primary retroperitoneal soft tissue sarcoma. Eur J Surg Oncol. 2007. 33:234–238.

19. Mussi C, Colombo P, Bertuzzi A, Coladonato M, Bagnoli P, Secondino S, et al. Retroperitoneal sarcoma: is it time to change the surgical policy? Ann Surg Oncol. 2011. 18:2136–2142.

20. Park JO, Qin LX, Prete FP, Antonescu C, Brennan MF, Singer S. Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule. Ann Surg. 2009. 250:977–982.

21. Shibata D, Lewis JJ, Leung DH, Brennan MF. Is there a role for incomplete resection in the management of retroperitoneal liposarcomas? J Am Coll Surg. 2001. 193:373–379.

22. Hu KS, Harrison LC. Adjuvant radiation therapy of retroperitoneal sarcoma: the role of intraoperative radiotherapy (IORT). Sarcoma. 2000. 4:11–16.

23. Jones JJ, Catton CN, O'Sullivan B, Couture J, Heisler RL, Kandel RA, et al. Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma. Ann Surg Oncol. 2002. 9:346–354.

24. Pisters PW, Ballo MT, Fenstermacher MJ, Feig BW, Hunt KK, Raymond KA, et al. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol. 2003. 21:3092–3097.

25. Strander H, Turesson I, Cavallin-Stahl E. A systematic overview of radiation therapy effects in soft tissue sarcomas. Acta Oncol. 2003. 42:516–531.

26. Tzeng CW, Fiveash JB, Heslin MJ. Radiation therapy for retroperitoneal sarcoma. Expert Rev Anticancer Ther. 2006. 6:1251–1260.

27. Zagar TM, Shenk RR, Kim JA, Harpp D, Kunos CA, Abdul-Karim FW, et al. Radiation therapy in addition to gross total resection of retroperitoneal sarcoma results in prolonged survival: results from a single institutional study. J Oncol. 2008. 2008:824036.

28. Tseng WH, Martinez SR, Do L, Tamurian RM, Borys D, Canter RJ. Lack of survival benefit following adjuvant radiation in patients with retroperitoneal sarcoma: a SEER analysis. J Surg Res. 2011. 168:e173–e180.

29. de Vreeze RS, de Jong D, Tielen IH, Ruijter HJ, Nederlof PM, Haas RL, et al. Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis. Mod Pathol. 2009. 22:223–231.

30. Crago AM, Singer S. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol. 2011. 23:373–378.

31. Hosaka A, Masaki Y, Yamasaki K, Aoki F, Sugizaki K, Ito E. Retroperitoneal mixed-type liposarcoma showing features of four different subtypes. Am Surg. 2008. 74:1202–1205.

32. Salemis NS, Tsiambas E, Karameris A, Tsohataridis E. Giant retroperitoneal liposarcoma with mixed histological pattern: a rare presentation and literature review. J Gastrointest Cancer. 2009. 40:138–141.

33. de Vreeze RS, de Jong D, Koops W, Nederlof PM, Ariaens A, Haas RL, et al. Oncogenesis and classification of mixed-type liposarcoma: a radiological, histopathological and molecular biological analysis. Int J Cancer. 2011. 128:778–786.